A Phase 1 interventional study of Experimental: B244 in Eczema and Atopic Dermatitis, sponsored by AOBiome LLC. Completed at 6 sites in United States. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-08-05.
Sponsored by AOBiome LLC · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Eczema with a site in United States — 33 open to participants now, 47 under way, 9 of them phase 3. Eczema · United States.
Among the 251 studies in Eczema with a site in United States, this one is the 173rd largest by enrollment of the 216 interventional ones that give a count, is one of 26 that started in 2018, is one of 18 in phase 1, and was the 117th registered.
506 studies on the registry are indexed under Eczema; 90 are open to participants now.
Browse Eczema studies →33 of the 251 studies in Eczema with a site in United States are open now. Recruiting first, the newest first:
Weill Medical College of Cornell University · Sites in United States
Ages 13–17
Arcutis Biotherapeutics, Inc. · Sites in United States
Ages 6+
Pfizer · Sites in United States, Canada, Japan and 1 more country
Ages 12+
Pfizer · Sites in United States, Canada, Japan
Ages 12+
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 66 Eczema studies recruiting now, 31 (47%) set no upper age limit and 27 (41%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 23 · Phase 2 83 · Phase 3 56 · Phase 4 17
First in 2003; this study’s year is marked. 26 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 91 across 403 interventional studies indexed under Eczema.
Median enrollment 102 across the 216 interventional studies, 243 across the 34 observational. Of the 182 that completed or were terminated, 111 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
164 of 251 have an industry lead sponsor. The 10 most frequent:
AOBiome LLC is the lead sponsor of 12 studies on the registry; 1 is open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
AOBiome LLC has 3 studies filed under Eczema — fewer than ten, so there is no comparison to draw.
14 of the studies in Eczema with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07355075Phase 3Turn TherapeuticsA Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema) | 2027-01-20 |
| NCT06807268Phase 3PfizerA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema | 2027-05-02 |
| NCT07265479Phase 3Organon and CoA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis | 2027-08 |
| NCT06928246Daniel KaplanThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis | 2026-12-15 |
| NCT06504160National Institute of Allergy and Infectious Diseases (NIAID)Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) | 2026-12-24 |
Add all 14 to your calendar (.ics) → With an account.
Among the 251 studies in Eczema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open-label, multicenter, Phase Ib study of B244 delivered as a topical spray to assess safety in pediatric subjects aged 2 to 17 years with atopic dermatitis
Condition or disease Intervention/treatment Phase Atopic Dermatitis (Eczema) Biological: B244 Phase 1b
This is a Phase 1b, open-label, single arm, multiple site study assessing twice daily B244 application for 28 days in pediatric subjects with mild to moderate atopic dermatitis.
Number of Subjects:
The study will enroll 36 subjects in 3 cohorts of 12 subjects:
At Screening and Baseline, all subjects must have confirmed diagnosis of atopic dermatitis, as defined by the Hanifin and Rajka criteria, which involves a minimum of 10% but no more than 60% body surface area and a Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) scale of 2 or 3.
The duration of the study will be approximately 7 weeks. Subjects will attend for a Screening visit between Days -21 and -14. If all eligibility criteria and none of the exclusion criteria are met, subjects will be enrolled into the study and will be required to undergo a 14 day washout period (Days-14 to -1). Subjects will attend the study center on Day 1 and the Baseline assessments will be performed before application of the first dose.
On confirmation of continued eligibility the subject and parent or guardian of the subject will be coached on how to apply medication, depending on the affected areas. They will be instructed to apply B244 twice daily (approximately 12 hours apart) for 28 days.
The first dose will be applied in the clinic under the supervision of clinical staff. Details of dose administration will be recorded in the study diary provided. The subjects with their parent or guardian will return to the study center on Days 7, 14, and 21 for completion of study assessments.
There will be a final study visit on Day 28, this will be defined as the end of the study for the subjects. A time window of ±2 day will be permitted for these 4 visits. There will not be a period of confinement in the study center all visits will be outpatient visits. Safety monitoring will include review of TEAEs, vital signs and physical examination. Efficacy will be assessed using EASI, vIGA-AD scale, POEM and ItchMan scores.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects are eligible to be included in the study only if all of the following criteria apply:
Exclusion Criteria:
Subjects are excluded from the study if any of the following criteria apply:
<!-- -->
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
B244 suspension in 30ml/bottle
Drug: Experimental: B244
B244 suspension in 30ml/bottle
Number of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.0
Safety and tolerability endpoints will consist of all adverse events reporting from Baseline to Day 28.
Time frame: Baseline to Day 28
Number of Participants With Clinically Significant Changes From Baseline in Physical Exam.
A physical exam will be conducted by a physician assessing systems (General appearance, Dermatological, Musculoskeletal, Thyroid, HEENT \[Head, eyes, ears, nose, throat\], Lymphatic, Respiratory, Gastrointestinal, Cardiovascular, Neurological, Extremities, and other). Clinical significance of the physical exam will be determined at investigator's discretion. Results for each system were assessed as Normal, Abnormal CS (clinically significant), or Abnormal NCS (not clinically significant) and shift was analyzed from Baseline to Day 28.
Time frame: Baseline to Day 28
Mean Change in Blood Pressure From Baseline at Day 28
Blood pressure will be obtained (mmHg). Clinical significance of blood pressure will be determined at the investigator's discretion. Change from Day 28 to Baseline.
Time frame: Baseline to Day 28
Mean Change in Pulse Rate From Baseline at Day 28
Pulse rate (beats per minute \[bpm\]) will be obtained. Clinical significance of pulse rate will be determined at the investigator's discretion. Change from Day 28 to Baseline.
Time frame: Baseline to Day 28
Mean Change in Body Temperature From Baseline at Day 28
Body temperature (°C) will be obtained. Clinical significance of body temperature will be determined at the investigator's discretion. Change from Day 28 to Baseline.
Time frame: Baseline to Day 28
Changes in the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD).
The vIGA-AD is a physician assessment ranking of Atopic Dermatitis symptoms from 0-clear, to 4- severe.
Time frame: Baseline, Days 7, 14, 21, and 28
Changes in Area Severity Index (EASI) Score.
EASI is a validated tool used to measure the severity and extent of atopic dermatitis where clinical investigators assess the presence and severity of erythema, edema/papulation, excoriation, and lichenification (score 0-3: none=0, mild=1, moderate=2, severe=3, half-points allowed) and area of involvement (score 0-6: 0=0% involvement, 1=1-9% involvement, 2=10-29% involvement, 3=30-49% involvement, 4=50-69% involvement, 5=70-89% involvement, 6=90-100% involvement) across head and neck, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks). The EASI score can range from 0.0 to 72.0 with increments of 0.1 and higher scores representing a greater severity of atopic dermatitis.
Time frame: Baseline, Days 7, 14, 21, and 28
Changes in Patient Oriented Eczema Measure (POEM Total Score).
POEM is a survey that consists of 7 questions that assesses the quality of life of patient's with eczema to determine their disease severity. The 7 questions are scored out of 4 points based on frequency of occurrence during the prior week (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days). A higher total score indicates a higher severity of disease (0 \[clear\] to 28 \[very severe\]).
Time frame: Baseline, Days 7, 14, 21, and 28
Changes in Patient Reported Outcome (Self-reported ItchMan Scale).
The Burn Man Itch Scale is used as a self report tool for subjects to indicate how itchy the area of atopic dermatitis feels at the timepoints during the study. It's reported on a scale between 0-comfortable, no itch and 4-Itches most terribly; impossible to sit still; concentrate.
Time frame: Baseline, Days 7, 14, 21, and 28
| Milestone | B244 |
|---|---|
| Started | 28 |
| Completed | 25 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Withdrawal by subject | 1 |
Safety and tolerability endpoints will consist of all adverse events reporting from Baseline to Day 28.
| Participants | B244 |
|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs)as Assessed by CTCAE v4.0 | 11 |
A physical exam will be conducted by a physician assessing systems (General appearance, Dermatological, Musculoskeletal, Thyroid, HEENT \[Head, eyes, ears, nose, throat\], Lymphatic, Respiratory, Gastrointestinal, Cardiovascular, Neurological, Extremities, and other). Clinical significance of the physical exam will be determined at investigator's discretion. Results for each system were assessed as Normal, Abnormal CS (clinically significant), or Abnormal NCS (not clinically significant) and shift was analyzed from Baseline to Day 28.
| Participants | B244 |
|---|---|
| Cardiovascular: Normal -> Normal | 25 |
| Dermatological: Normal -> Abnormal CS | 1 |
| Dermatological: Normal -> Normal | 24 |
| Extremities: Normal -> Normal | 25 |
| Gastrointestinal: Normal -> Normal | 25 |
| General Appearance: Abnormal NCS -> Abnormal NCS | 1 |
| General Appearance: Normal -> Normal | 24 |
| HEENT: Abnormal CS-> Normal | 1 |
| HEENT: Normal -> Normal | 24 |
| Lymphatic: Normal -> Normal | 25 |
| Musculoskeletal: Normal -> Normal | 25 |
| Neurological: Normal -> Normal | 25 |
| Respiratory: Normal -> Abnormal NCS | 1 |
| Respiratory: Normal -> Normal | 24 |
| Thyroid: Missing -> Normal | 1 |
| Thyroid: Normal -> Normal | 24 |
Blood pressure will be obtained (mmHg). Clinical significance of blood pressure will be determined at the investigator's discretion. Change from Day 28 to Baseline.
| mmHg | B244 |
|---|---|
| Diastolic Blood Pressure | 1.6 ± 9.3 |
| Systolic Blood Pressure | 1.8 ± 10.8 |
The vIGA-AD is a physician assessment ranking of Atopic Dermatitis symptoms from 0-clear, to 4- severe.
| Participants | B244 |
|---|---|
| Change from Baseline on Day 7 — 4 - Worsen by 4 grades | 0 |
| Change from Baseline on Day 7 — 3 - Worsen by 3 grades | 0 |
| Change from Baseline on Day 7 — 2 - Worsen by 2 grades | 0 |
| Change from Baseline on Day 7 — 1 - Worsen by 1 grade | 2 |
| Change from Baseline on Day 7 — No change | 23 |
| Change from Baseline on Day 7 — -1 - Improved by 1 grade | 1 |
| Change from Baseline on Day 7 — -2 - Improved by 2 grades | 0 |
| Change from Baseline on Day 7 — -3 - Improved by 3 grades | 0 |
| Change from Baseline on Day 7 — -4 - Improved by 4 grades | 0 |
| Change from Baseline on Day 14 — 4 - Worsen by 4 grades | 0 |
| Change from Baseline on Day 14 — 3 - Worsen by 3 grades | 0 |
| Change from Baseline on Day 14 — 2 - Worsen by 2 grades | 0 |
| Change from Baseline on Day 14 — 1 - Worsen by 1 grade | 2 |
| Change from Baseline on Day 14 — No change | 20 |
| Change from Baseline on Day 14 — -1 - Improved by 1 grade | 3 |
| Change from Baseline on Day 14 — -2 - Improved by 2 grades | 0 |
| Change from Baseline on Day 14 — -3 - Improved by 3 grades | 0 |
| Change from Baseline on Day 14 — -4 - Improved by 4 grades | 0 |
| Change from Baseline on Day 21 — 4 - Worsen by 4 grades | 0 |
| Change from Baseline on Day 21 — 3 - Worsen by 3 grades | 0 |
| Change from Baseline on Day 21 — 2 - Worsen by 2 grades | 0 |
| Change from Baseline on Day 21 — 1 - Worsen by 1 grade | 2 |
| Change from Baseline on Day 21 — No change | 17 |
| Change from Baseline on Day 21 — -1 - Improved by 1 grade | 6 |
| Change from Baseline on Day 21 — -2 - Improved by 2 grades | 0 |
| Change from Baseline on Day 21 — -3 - Improved by 3 grades | 0 |
| Change from Baseline on Day 21 — -4 - Improved by 4 grades | 0 |
| Change from Baseline on Day 28 — 4 - Worsen by 4 grades | 0 |
| Change from Baseline on Day 28 — 3 - Worsen by 3 grades | 0 |
| Change from Baseline on Day 28 — 2 - Worsen by 2 grades | 0 |
| Change from Baseline on Day 28 — 1 - Worsen by 1 grade | 2 |
| Change from Baseline on Day 28 — No change | 17 |
| Change from Baseline on Day 28 — -1 - Improved by 1 grade | 5 |
| Change from Baseline on Day 28 — -2 - Improved by 2 grades | 1 |
| Change from Baseline on Day 28 — -3 - Improved by 3 grades | 0 |
| Change from Baseline on Day 28 — -4 - Improved by 4 grades | 0 |
EASI is a validated tool used to measure the severity and extent of atopic dermatitis where clinical investigators assess the presence and severity of erythema, edema/papulation, excoriation, and lichenification (score 0-3: none=0, mild=1, moderate=2, severe=3, half-points allowed) and area of involvement (score 0-6: 0=0% involvement, 1=1-9% involvement, 2=10-29% involvement, 3=30-49% involvement, 4=50-69% involvement, 5=70-89% involvement, 6=90-100% involvement) across head and neck, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks). The EASI score can range from 0.0 to 72.0 with increments of 0.1 and higher scores representing a greater severity of atopic dermatitis.
| score on a scale | B244 |
|---|---|
| Change from Baseline to Day 7 | -0.31 ± 2.920 |
| Change from Baseline to Day 14 | -1.30 ± 4.088 |
| Change from Baseline to Day 21 | -1.98 ± 4.693 |
| Change from Baseline to Day 28 | -2.31 ± 4.109 |
POEM is a survey that consists of 7 questions that assesses the quality of life of patient's with eczema to determine their disease severity. The 7 questions are scored out of 4 points based on frequency of occurrence during the prior week (0 = no days, 1 = 1 to 2 days, 2 = 3 to 4 days, 3 = 5 to 6 days, and 4 = all days). A higher total score indicates a higher severity of disease (0 \[clear\] to 28 \[very severe\]).
| score on a scale | B244 |
|---|---|
| Change from Baseline to Day 7 | -1.2 ± 4.68 |
| Change from Baseline to Day 14 | -4.2 ± 5.21 |
| Change from Baseline to Day 21 | -4.4 ± 6.10 |
| Change from Baseline to Day 28 | -4.2 ± 7.03 |
The Burn Man Itch Scale is used as a self report tool for subjects to indicate how itchy the area of atopic dermatitis feels at the timepoints during the study. It's reported on a scale between 0-comfortable, no itch and 4-Itches most terribly; impossible to sit still; concentrate.
| score on a scale | B244 |
|---|---|
| Change from Baseline to Day 7 | -0.2 ± 0.92 |
| Change from Baseline to Day 14 | -0.8 ± 1.20 |
| Change from Baseline to Day 21 | -0.6 ± 1.26 |
| Change from Baseline to Day 28 | -0.8 ± 1.40 |
Pulse rate (beats per minute \[bpm\]) will be obtained. Clinical significance of pulse rate will be determined at the investigator's discretion. Change from Day 28 to Baseline.
| bpm | B244 |
|---|---|
| Mean Change in Pulse Rate From Baseline at Day 28 | 3.9 ± 15.3 |
Body temperature (°C) will be obtained. Clinical significance of body temperature will be determined at the investigator's discretion. Change from Day 28 to Baseline.
| °C | B244 |
|---|---|
| Mean Change in Body Temperature From Baseline at Day 28 | -0.2 ± 0.6 |
Collected over Baseline to Day 28. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| B244 | 0/28 (0%) | 0/28 (0%) | 11/28 (39.3%) |
| Event | B244 |
|---|---|
| NasopharyngitisInfections and infestations | 2/28 |
| PruritusSkin and subcutaneous tissue disorders | 2/28 |
| LymphadenopathyBlood and lymphatic system disorders | 1/28 |
| VomitingGastrointestinal disorders | 1/28 |
| MalaiseGeneral disorders | 1/28 |
| PyrexiaGeneral disorders | 1/28 |
| Localized infectionInfections and infestations | 1/28 |
| SinusitisInfections and infestations | 1/28 |
| Tibia fractureInjury, poisoning and procedural complications | 1/28 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/28 |
ITT population: All subjects who were enrolled and took at least 1 dose of study treatment.
| Age, Customized(years) | B244 |
|---|---|
| Mean | 7.4 ± 4.80 |
| Sex: Female, Male(Participants) | B244 |
|---|---|
| Female | 15 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | B244 |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 22 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | B244 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 23 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Percentage of Total Body Surface Area Affected by Atopic Dermatitis(% of total body surface area) | B244 |
|---|---|
| Mean | 17.98 ± 7.581 |
| Baseline vIGA-AD Score(Participants) | B244 |
|---|---|
| 2=Mild | 11 |
| 3=Moderate | 17 |
| Weight(kg) | B244 |
|---|---|
| Mean | 36.22 ± 30.599 |
| Height(cm) | B244 |
|---|---|
| Mean | 124.0 ± 29.95 |
1 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in May 2019, 5 months.
Results were first posted in Aug 2024, 5 years 2 months after primary completion.
Of 16 phase 1 interventional studies under Eczema, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 20. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nitrosomonas eutropha D23
AOBiome LLC